News
BETRF
0.180
0.00%
0.000
BetterLife Pharma Taps LifeSci Advisors as It Advances BETR-001 Toward 2027 Clinical Milestones
TipRanks · 5d ago
BetterLife Pharma Appoints LifeSci Advisors as Investor Relations Firm
Newsfile · 5d ago
Weekly Report: what happened at BETRF last week (1019-1023)?
Weekly Report · 6d ago
BetterLife Pharma Strengthens Headache Program with New Scientific Advisory Co-Chair
TipRanks · 10/19 13:10
BetterLife Pharma Appoints Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board
Newsfile · 10/19 12:00
Weekly Report: what happened at BETRF last week (1012-1016)?
Weekly Report · 10/19 10:24
BetterLife Pharma Taps Clinical Veteran to Lead BETR-001 First-in-Human Study
TipRanks · 10/15 13:18
BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical Operations
Newsfile · 10/15 12:00
BetterLife Pharma Taps Migraine Pioneer to Lead BETR-001 Headache Program
TipRanks · 10/14 13:05
BetterLife Pharma Establishes Scientific Advisory Board for Headache Program; Professor Peter Goadsby Appointed Co-Chair
Newsfile · 10/14 12:00
Weekly Report: what happened at BETRF last week (1005-1009)?
Weekly Report · 10/12 10:30
BetterLife Pharma Faces Legal Dispute With Director Over Convertible Debenture
TipRanks · 10/09 20:39
BetterLife Pharma Addresses Notice of Civil Claim Filed by Steven Sangha
Newsfile · 10/09 19:00
Weekly Report: what happened at BETRF last week (0928-1002)?
Weekly Report · 10/05 10:29
BetterLife Pharma Resets Shareholder Meeting to Advance Nasdaq Listing Plans
TipRanks · 09/30 01:02
BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting
Newsfile · 09/29 21:59
Weekly Report: what happened at BETRF last week (0921-0925)?
Weekly Report · 09/28 10:24
Weekly Report: what happened at BETRF last week (0914-0918)?
Weekly Report · 09/21 10:24
BetterLife Pharma Raises US$100 Million to Advance Neurological Drug BETR-001
TipRanks · 09/17 15:03
BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
Newsfile · 09/17 14:41
More
Webull provides a variety of real-time BETRF stock news. You can receive the latest news about Betterlife Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About BETRF
BetterLife Pharma Inc. is a biotechnology company. The Company is primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical, is a non-hallucinogenic second-generation lysergic acid diethylamide (LSD) derivative molecule that mimics the projected therapeutic potential of LSD in the treatment of disorders, such as depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders. BETR-002, which is in preclinical, is a formulation of a derivative of dihydrohonokiol, a known anti-anxiety compound, with the potential for treatment of anxiety related disorders, including benzodiazepine dependency. It is also refining and developing drug candidates from a set of complementary interferon-based technologies, which have the potential to engage the immune system to fight viral infections.